Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

Robert Gould Biography and Net Worth

Insider of Fulcrum Therapeutics

Robert J. Gould joined Fulcrum as president and CEO at the time of the company’s launch in 2016, bringing over 30 years of experience to the role. Previously, he served as president and CEO of Epizyme from 2010 to 2015. Prior to joining Epizyme, Robert served as director of novel therapeutics at Broad Institute of MIT and Harvard from 2006 to 2010. Robert spent 23 years at Merck where he held a variety of leadership positions, culminating in the role of vice president, licensing and external research. During his time at Merck, Robert was instrumental in advancing more than 20 compounds from discovery into clinical development in multiple therapeutic areas. Robert received a bachelor’s from Spring Arbor University and a Ph.D. from the University of Iowa and completed postdoctoral studies at Johns Hopkins University.

What is Robert J. Gould's net worth?: The estimated net worth of Robert J. Gould is at least $3.57 million as of January 13th, 2023. Dr. Gould owns 499,864 shares of Fulcrum Therapeutics stock worth more than $3,574,028 as of April 17th. This net worth evaluation does not reflect any other investments that Dr. Gould may own. Learn More about Robert J. Gould's net worth.
How do I contact Robert J. Gould?: The corporate mailing address for Dr. Gould and other Fulcrum Therapeutics executives is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. Fulcrum Therapeutics can also be reached via phone at (617) 651-8851 and via email at [email protected]. Learn More on Robert J. Gould's contact information.
Has Robert J. Gould been buying or selling shares of Fulcrum Therapeutics?: Robert J. Gould has not been actively trading shares of Fulcrum Therapeutics over the course of the past ninety days. Most recently, Robert J. Gould sold 6,766 shares of the business's stock in a transaction on Friday, January 13th. The shares were sold at an average price of $15.00, for a transaction totalling $101,490.00. Following the completion of the sale, the chief executive officer now directly owns 499,864 shares of the company's stock, valued at $7,497,960. Learn More on Robert J. Gould's trading history.
Who are Fulcrum Therapeutics' active insiders?: Fulcrum Therapeutics' insider roster includes James Geraghty (Director), Robert Gould (Insider), Christopher Morabito (Insider), Curtis Oltmans (SVP), and Peter Thomson (CEO). Learn More on Fulcrum Therapeutics' active insiders.
Are insiders buying or selling shares of Fulcrum Therapeutics?: During the last year, insiders at the sold shares 2 times. They sold a total of 5,094 shares worth more than $57,935.58. The most recent insider tranaction occured on March, 8th when VP Greg Tourangeau sold 4,884 shares worth more than $57,240.48. Insiders at Fulcrum Therapeutics own 2.5% of the company. Learn More about insider trades at Fulcrum Therapeutics.
Information on this page was last updated on 3/8/2024.

Robert J. Gould Insider Trading History at Fulcrum Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/13/2023	Sell	6,766	$15.00	$101,490.00	499,864
6/6/2022	Sell	24,382	$8.10	$197,494.20	506,630
6/3/2022	Sell	25,551	$7.95	$203,130.45	506,630
4/7/2022	Sell	5,631	$24.02	$135,256.62	506,630
4/4/2022	Sell	7,235	$24.02	$173,784.70	506,630
4/1/2022	Sell	34,464	$24.03	$828,169.92	506,630
3/15/2021	Sell	9,211	$12.13	$111,729.43	507,419
1/20/2021	Sell	10,000	$12.08	$120,800.00	524,845
7/8/2020	Sell	2,500	$20.00	$50,000.00	534,845
6/25/2020	Sell	2,500	$20.80	$52,000.00	537,345
6/3/2020	Sell	1,500	$20.13	$30,195.00	544,734
5/28/2020	Sell	1,919	$20.01	$38,399.19	550,426

Robert J. Gould Buying and Selling Activity at Fulcrum Therapeutics

Fulcrum Therapeutics Company Overview

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $7.15

$7.13

$7.51

50 Day Range

MA: $9.58

$7.15

$12.00

2 Week Range

Now: $7.15

$2.42

$13.70

Volume

397,383 shs

Average Volume

655,908 shs

Market Capitalization

$442.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.29

The “Perfect Storm” for Gold

From Gold Safe Exchange | Ad